GE HealthCare Technologies Inc. (GEHC)
GEHC vs. BSX: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?
GE HealthCare: This Drop Represents A Buying Opportunity
GE HealthCare Technologies delivered strong Q2 results, beating revenue and earnings expectations, and raised full-year guidance despite a sharp share price drop. The company is trading at a significant discount to peers, offering substantial upside potential even at the low end of industry valuation multiples. Management is actively mitigating tariff impacts, investing in innovation, and launching new products to drive future growth and operational efficiency.
GE HealthCare Q2 Earnings & Sales Beat Estimates, Net Margin Rises
GEHC's second-quarter results reflect strength in the Imaging and Pharmaceutical Diagnostics segments. The bottom line improves with better pricing.
Compared to Estimates, GE HealthCare (GEHC) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for GE HealthCare (GEHC) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
GE HealthCare Tops Estimates, Lifts Profit Outlook on Smaller Tariff Impact
GE HealthCare (GEHC) on Wednesday reported better second-quarter results than analysts had expected and lifted its outlook for the full year.
GE HealthCare Technologies (GEHC) Q2 Earnings and Revenues Top Estimates
GE HealthCare Technologies (GEHC) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1 per share a year ago.
GE HealthCare Stock Rises as Earnings Beat. How Tariff Pressures Are Easing.
Wednesday, GE HealthCare reported earnings per share of $1.06 from sales of just over $5 billion. Wall Street was looking for EPS of 92 cents from sales of just under $5 billion.
Should You Buy, Sell, or Hold GE Healthcare Before Q2 Earnings?
GEHC leans on Imaging and PDx strength for Q2, but tariff headwinds and margin pressures could test investor confidence.
GE HealthCare Stock: Hidden Winner Of Alzheimer's Drug Boom
GE HealthCare Technologies is one of the leaders in the healthcare sector, with a strong position in the global molecular imaging market. GE HealthCare's Pharmaceutical Diagnostics segment's EBIT was $205 million in Q1 2025, up 15.2% year over year. I expect it to rise to $245 million in Q2, driven by increased sales of Vizamyl, which is used to prescribe anti-amyloid drugs for the treatment of Alzheimer's disease.
GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications
GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.
GE Healthcare: Near-Term Margin Headwinds Priced In, Long-Term Growth Driven By New Products And M&As
GE Healthcare is well-positioned for growth, driven by a strong backlog, product innovation, and potential pent-up demand in China as stimulus funding is deployed. Margin headwinds from tariffs are expected to bottom in Q3, with management actively mitigating impacts through cost controls, local manufacturing, and pricing actions. Valuation is attractive versus peers, with current prices reflecting tariff risks and offering upside as margins recover and growth accelerates post-Q3.
GE HealthCare Stock Slips Despite the Launch of bkActiv S Series
GEHC expands its bkPortfolio with the AI-powered bkActiv S Series to advance ultrasound-guided procedures.
